See more : Mid-America Apartment Communities, Inc. (0K1E.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (SDZNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Cedar Woods Properties Limited (CWP.AX) Income Statement Analysis – Financial Results
- Adstar Inc (ADST) Income Statement Analysis – Financial Results
- PT Tempo Scan Pacific Tbk (TSPC.JK) Income Statement Analysis – Financial Results
- Stifel Financial Corp. (SF-PD) Income Statement Analysis – Financial Results
- National Energy Services Reunited Corp (NESRW) Income Statement Analysis – Financial Results
Sandoz Group AG (SDZNY)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.86B | 8.79B | 9.04B |
| Cost of Revenue | 5.42B | 4.71B | 4.64B | 4.88B |
| Gross Profit | 4.56B | 4.15B | 4.15B | 4.16B |
| Gross Profit Ratio | 45.74% | 46.87% | 47.20% | 45.99% |
| Research & Development | 926.00M | 795.57M | 832.90M | 819.41M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39B | 22.50K | 1.94B | 2.00B |
| Other Expenses | 874.00M | 8.60M | 6.40M | 5.63M |
| Operating Expenses | 4.19B | 22.50K | 2.77B | 2.81B |
| Cost & Expenses | 9.60B | 22.50K | 7.41B | 7.69B |
| Interest Income | 31.00M | 7.64M | 4.57M | 2.82M |
| Interest Expense | 202.00M | 84.05M | 61.26M | 70.40M |
| Depreciation & Amortization | 525.00M | 437.42M | 447.08M | 650.46M |
| EBITDA | 857.00M | 1.68B | 1.83B | 1.99B |
| EBITDA Ratio | 8.59% | 0.00% | 20.77% | 22.03% |
| Operating Income | 375.00M | -22.50K | 1.38B | 1.34B |
| Operating Income Ratio | 3.76% | 0.00% | 15.69% | 14.83% |
| Total Other Income/Expenses | -245.00M | -137.00M | -179.20M | -677.68M |
| Income Before Tax | 130.00M | -22.50K | 1.20B | 662.66M |
| Income Before Tax Ratio | 1.30% | 0.00% | 13.65% | 7.33% |
| Income Tax Expense | 50.00M | 361.00 | 368.45M | 227.14M |
| Net Income | 77.00M | -22.86K | 830.15M | 433.64M |
| Net Income Ratio | 0.77% | 0.00% | 9.44% | 4.80% |
| EPS | 0.18 | 0.00 | 1.93 | 1.01 |
| EPS Diluted | 0.18 | 0.00 | 1.93 | 1.01 |
| Weighted Avg Shares Out | 429.90M | 431.00M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 431.00M | 431.00M | 431.00M |
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European...
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right...
Sandoz reports third-quarter and nine-month 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches Generics growth acceleration driven by Europe Third-quarter net sales¹ of USD 2.6...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 –...
Sandoz Canada achieves carbon neutral certification for its commercial operations
BOUCHERVILLE, Quebec, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada obtained carbon neutral certification from the engineering consulting firm LCL Engineering, Environment & Sustainable Development for its Boucherville head office and business travel activities. This certification attests to the company's...
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Source: https://incomestatements.info
Category: Stock Reports